17β-Estradiol Primes Elicitation of Inducible Nitric Oxide Synthase Expression by Lipopolysaccharide and Interferon-γ in Mouse Macrophage Cell Line J774.1

Humitoshi Sakazaki, Ryoko Ido, Hitoshi Ueno, and Katsuhiko Nakamuro*

Division of Environmental Health, Faculty of Pharmaceutical Sciences, Setsunan University, 45–1 Nagaotoge-cho, Hirakata, Osaka 573–0101, Japan

(Received October 12, 2004; Accepted November 9, 2004; Published online November 11, 2004)

The effects of estrogenic compounds on nitric oxide (NO) production by macrophages were examined. 17β-Estradiol promoted NO production triggered by lipopolysaccharide (LPS) and/or interferon (IFN)-γ in the mouse macrophage cell line J774.1. Other estrogen-like substances such as estrone, 17α-ethynylestradiol and bisphenol A also enhanced NO synthesis, but this NO synthesis was not activated by Ca2+ ionophore A23187. RT-PCR analysis demonstrated induction of inducible nitric oxide synthase (iNOS) mRNA in J774.1 cells exposed to 17β-estradiol. Although the estrogen receptor (ER)-antagonist ICI-182780 partially suppressed the promoting effect of 17β-estradiol on NOS activity, there was little ERα detectable by RT-PCR from J774.1 cells. These results suggest that ERs may participate only partially in iNOS mRNA transcription in J774.1 cells and that 17β-estradiol may act directly through other unknown intracellular signal transduction(s) that are activated by LPS and IFN-γ.

Key words —— 17β-estradiol, macrophage, nitric oxide, endocrine disrupting chemical

INTRODUCTION

Endocrine hormones play important roles in cell differentiation, growth and the reproductive functions of humans and animals. The endocrine system, immune system and nervous system affect each other, and these three systems organize higher regulation systems to maintain homeostasis in the body.1) The female hormone estrogen is involved not only with female phenotypes but also has both beneficial and adverse effects on human health.2,3) For example, estrogens are used postmenopausally for treatment of osteoporosis4) or vasomotor neuropathy.5) However, estrogen has been incriminated in the onset of cardiovascular diseases,6) apoplexy,7) various neurodegenerative diseases including Alzheimer-type dementia,8) and promotion of carcinogenesis in the breast9) and endometrium.10) Moreover, estrogen increases the risk of developing autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis.11,12) Additionally, it is reported that chemicals discharged into the environment may cause abnormalities in human reproduction and wildlife breeding. These environmental pollutants are called endocrine disrupting chemicals (EDCs), and some of them show estrogen-like actions in biological systems.13) These EDCs may also exert the adverse actions of endogenous estrogen.

In immune responses, immunocompetent cells infiltrate affected areas to destroy xenobiotics or execute phagocytosis of them. This infiltration of cells and the humoral factors released cause inflammation characterized by pain, fever, flaring and swelling. These symptoms often disturb the normal functions of inflamed tissues. A continuous inflammation may result in an ulcer and sometimes necrosis of the tissue. Thus, the immune response has both useful effects and detrimental actions. This inconsistency is partially due to nitric oxide (NO). NO, as well as super oxide anion, is produced mainly by macrophages during the immune response and damages tumors or microorganisms.14) NO promotes inflammation and immune responses, controls proliferation of T cells by stopping the cell cycle progres-
sion in the G1/S phase\textsuperscript{15} and suppresses the degranulation of mast cells.\textsuperscript{16} On the other hand, a high-level of NO can injure normal tissues. In one of the autoimmune diseases, type I diabetes, the activated macrophage-secreted NO injures β cells of the islets of Langerhans in the pancreas.\textsuperscript{17} NO production rises in the inflamed regions of patients suffering from autoimmune diseases and causes various injuries in organs and tissues.\textsuperscript{18}

NO is produced by the enzymatic oxidation of L-arginine. There are three isozymes of nitric oxide synthase (NOS),\textsuperscript{19} endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS (iNOS), which are distributed primarily in vascular endothelium, nerve cells and macrophages, respectively. Of these isoforms, eNOS and nNOS are constitutively located on the cell membrane, and also called constitutive NOS (cNOS). Inducible NOS is distributed to macrophages and other leukocytes, and production is transiently stimulated by cytokines and lipopolysaccharides. It is generally known that production of NO by eNOS in vascular endothelial cells differs between the sexes, and much more tends to be produced in females than males.\textsuperscript{20,21} Therefore, 17β-estradiol may change eNOS into the active form by activating some intracellular kinase cascade. This activation may be triggered by an estrogen receptor (ER), which is one of the intranuclear receptors. Finally, NO promoted by 17β-estradiol prevents arteriosclerosis through repression of platelet agglutination and lymphocyte adhesion. It is also reported that 17β-estradiol may promote transcription of eNOS mRNA by binding to ERs in vascular endothelial cells.\textsuperscript{22,23} An ER was also found in mouse spleen lymphocytes.\textsuperscript{24} These data suggest that 17β-estradiol promotes transcription of iNOS mRNA through binding to an ER in lymphocytes to increase NO in the immune cells. However, little evidence that estrogen induces NO synthesis in the immune system has been shown.

In this research, the relevance of the actions of estrogens to NO synthesis in the mouse macrophage cell line J774.1\textsuperscript{25} was examined using the diaminofluorescein-2 (DAF-2) fluorescence method.\textsuperscript{26} The effects of EDCs on the production of NO were also examined using J774.1 cells, and the class of NOS producing NO in these cells and the involvement of ERs were determined.

**MATERIALS AND METHODS**

**Reagents** —— 17β-Estradiol was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Lipopolysaccharide, interferon (IFN)-γ, concanavalin A, L-arginine, and phenol-red-free RPMI-1640 medium were obtained from Sigma-Aldrich Inc. (St. Louis, MO, U.S.A.). DAF-2 and DAF-2T were purchased from Daiichi Pure Chemicals Co., Ltd. (Tokyo, Japan). The ER antagonist ICI-182780 was generously provided by AstraZeneca (London, U.K.). A23187 was obtained from Merck KgaA (Darmstadt, Germany). J774.1 cells were purchased from Japanese Collection of Research Biosources (Tokyo, Japan). All other reagents were of the highest grade commercially available.

**Cell Culture** —— J774.1 cells were cultured in RPMI-1640 medium under 5% CO\textsubscript{2} at 37°C. The RPMI-1640 medium was supplemented by 5 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 50 µM 2-mercaptoethanol, 50 mg/l potassium benzyl penicillin, 50 mg/l streptomycin sulfate, 0.18% NaHCO\textsubscript{3} and 10% fetal calf serum. Cells, 1 × 10\textsuperscript{5}, were put into each well of 48-well microplates with 500 µl of medium. 17β-Estradiol was added at the final concentration of 10\textsuperscript{-8} mol/l, and cells were incubated for 24 hr. Cells were washed with Krebs-Ringer buffer and cultured for a further 24 hr in new medium containing 10 mg/l lipopolysaccharide (LPS)\textsuperscript{27} and/or 0.2 µg/l IFN-γ.\textsuperscript{28} A Ca\textsuperscript{2+} ionophore, A23187,\textsuperscript{29} was added at the concentration of 2 mg/l to 2 × 10\textsuperscript{5} cells in each well and incubated for 30 min. The final concentration of dimethyl sulfoxide (DMSO), the vehicle of 17β-estradiol and A23187, was limited to 0.1%.

**Determination of NO** —— The DAF-2 fluorescence method was performed according to a previous report.\textsuperscript{26} The cultured cells were washed once with Krebs-Ringer buffer and incubated in 300 µl of the new buffer containing 100 µmol/l of L-arginine and 1 µmol/l of DAF-2 for 2 hr at 37°C. After incubation, 200 µl of the supernatant was transferred to a black 96-well microplate (Thermo Labsystems Oy., Helsinki, Finland), and the fluorescence of DAF-2T was measured at wavelengths of 490 nm for excitation and 520 nm for emission with an MTP-600F microplate reader (Corona Electric Co., Ltd., Ibaraki, Japan). The amount of extracellular NO was determined by a calibration curve using authentic DAF-2T. The total cellular amount was determined by the ethidium bromide fluorescence method.\textsuperscript{30,31} Briefly, the cells were washed once with 200 µl of PBS,
200 µl of 0.1% sodium dodecyl sulfate (SDS) was added, and they were left for 30 min to lyse. Then, 100 µl of 50 µg/ml ethidium bromide was added to each well, they were incubated for 15 min, and the complex formed by DNA and ethidium bromide was determined fluorometrically with emission at 620 nm and excitation at 515 nm with a microplate reader (MTP-200F, Corona Electric Co., Ltd.) as an indication of cell number. A calibration curve for cell was obtained to calculate the number of cells in a well.

RT-PCR of iNOS mRNA —— Ribonuclease (RNase)-free plastic and water were used throughout the assay. J774.1 cells were suspended in the phenol-red-free RPMI-1640 medium. Cells were homogenized in 1 ml of Sepazol (Nacalai Tesque, Inc., Kyoto, Japan) and underwent acid guanidine thiocyanate-phenol-chloroform extraction according to the manufacturer’s protocol. Five micrograms of total RNA were allowed for reverse transcription using the Superscript II Preamplification System (GibcoBRL Invitrogen Co., Carlsbad, CA, U.S.A.). All reactions were performed in a thermal cycler (Takara Bio Inc., Shiga, Japan). One µl of 100 µM iNOS primers (5′ GTCAACTGCAAGAGAAGCG 3′, 5′ GAGCTCCTCCAGAGGGGT AGG 3′) was used to amplify iNOS. The oligonucleotides used to amplify glyceraldehyde-3-phosphate dehydrogenase (G3PDH) mRNA were purchased from Clontech Laboratories, Inc. (Palo Alto, CA, U.S.A.). The primers for amplification of ERα were previously reported.33)

Statistical Analysis —— The data represent mean ± standard deviation of measurements obtained from triplicate samples. Statistical comparison between groups was performed using Student’s t-test. Statistical significance was set at p < 0.05.

RESULTS

17β-Estradiol Augments NO-Synthesis Elicited by LPS and IFN-γ

As shown in Fig. 1, the production of NO was detected from cells with LPS stimulation and from cells with IFN-γ stimulation, and greater production was detected from cells costimulated with LPS and IFN-γ. 17β-Estradiol itself did not induce NO. However, NO production was increased by pre-exposure to 10−8 mol/l 17β-estradiol in case of LPS stimulation, IFN-γ stimulation or costimulation of LPS and IFN-γ.

Bisphenol A, 17α-ethynylestradiol and estrone were also tested for their ability to increase NO production in J774.1 cells with LPS stimulation (Fig. 2). Concentrations of these chemicals were determined by the ratio of affinities to ERα estimated by a yeast two-hybrid assay34) so that each EDC exerted sufficient activity. None of them promoted NO production by themselves. However, all three chemicals enhanced the stimulating effect of LPS, which indicates that environmental EDCs also prime NO synthesis in macrophages. Of these substances, 17β-estradiol had the strongest effect on NO production in macrophages, and bisphenol A had a weaker effect than had been expected from its concentration and
its affinity to ERα.

Enhancement of 17β-Estradiol on Expression of iNOS mRNA

To identify the subtype of NOS, the Ca2+ dependency of NOS was investigated with the Ca2+ ionophore A23187 (Fig. 3). The NO productions tended to be enhanced by 10⁻⁴ mol/l, probably toxic concentration, of 17β-estradiol. Despite the presence of A23187 treatment, no enhancement in NOS activity was observed. These results suggest that 17β-estradiol promoted production of Ca2+-independent iNOS.

The transcription of iNOS mRNA in J774.1 cells exposed to 17β-estradiol was examined by RT-PCR (Fig. 4). The results showed that iNOS mRNA was induced by LPS and IFN-γ stimulation and that iNOS mRNA was not detected with only 17β-estradiol. However, when 17β-estradiol was added prior to LPS and/or IFN-γ, the quantity of iNOS mRNA was increased. These results indicate that 17β-estradiol promoted NO production by increasing iNOS mRNA.

Involvement of ER in NO Production

To examine the involvement of ERs in iNOS expression in J774.1 cells, the effect of an ER antagonist, ICI-182780, on 17β-estradiol-enhanced NO production was investigated (Fig. 5). ICI-182780 slightly inhibited the priming effect of 17β-estradiol on the NO production in J774.1 cells. However, the addition of a 10-times higher concentration of ICI-182780 to that of 17β-estradiol did not completely inhibit the NO production. Because the ER antagonist only partially inhibited the priming effect of 17β-estradiol on NO synthesis, the existence of ERα in
J774.1 cells was examined by the RT-PCR method. No ERα mRNA was detected in J774.1 cells, although ERα mRNA was observed in the testis, ovary and uterus of 5-week-old BALB/c mice used as positive controls (Fig. 6). These results suggest that 17β-estradiol enhanced the transcription of iNOS mRNA in J774.1 cells through a mechanism other than ERα.

**DISCUSSION**

The fact that autoimmune diseases such as SLE and rheumatoid arthritis tend to occur mainly in women generally suggests that estrogens affect the immune system. Induction of NO has been observed in inflamed tissues of patients suffering from these diseases and is suggested to be related to harmful actions of the immune system. 17β-Estradiol is well known to enhance NO production in vascular endothelial cells and nerve cells. On the other hand, it is still unclear whether 17β-estradiol enhances NO production in immune cells. Therefore the influence of 17β-estradiol on NO production in macrophages, which are reported to produce NO, was investigated.

The mouse macrophage cell line J774.1 produced NO after stimulation by LPS derived from Escherichia coli or IFN-γ. Further, the cells pre-exposed to 17β-estradiol produced more NO after they were stimulated with LPS and IFN-γ (Fig. 1), although 17β-estradiol itself failed to induce NO. These results suggest that 17β-estradiol primes NO production and augments the activities of macrophages when they attack bacteria or are stimulated by type-1 helper T cells.

Because 17β-estradiol promoted NO synthesis in macrophages stimulated by LPS and IFN-γ, we examined whether EDCs, which bind to ERs and act like estrogens, also increase the NO production in J774.1 cells with LPS stimulation. The EDCs tested were bisphenol A, a typical EDC used as a plasticizer of synthetic resin, 17α-ethynylestradiol, an artificial estrogen used therapeutically, and estrone, a metabolite of 17β-estradiol. These chemicals were added to the cells in sufficient concentration to bind ERα. The results indicate that the priming effect of bisphenol A was relatively weaker than that of the others (Fig. 2). This finding suggests that EDCs may affect NO synthesis of macrophages in a manner other than by binding to ERα.

NO is synthesized by an oxygenase domain and a reductase domain of NOS, which transfer an electron from an oxygen molecule to a guanidinoacetic group of an L-arginine molecule and release molecular NO. NOS is classified into three types of isozymes, eNOS, nNOS and iNOS, found mainly in vascular endothelium, nerve cells and macrophages, respectively. Among those, eNOS and nNOS are located constitutively at or near the cell membrane and activated by binding to intracellular calcium ion, or activated through phosphorylation by a phosphatidylinositol-3-kinase (PI3K)-Akt pathway. On the other hand, iNOS is not always present in cells and is induced transiently in immune cells and hepatocytes by cytokine or LPS stimulation; iNOS is located in the cytoplasm. Because Ca²⁺ binds iNOS constitutively, iNOS is not further activated by an influx of Ca²⁺ into cells.

Some reports showed that 17β-estradiol bound to ERs on the membrane of mouse T cells and elevated the intracellular concentration of Ca²⁺. This influx of Ca²⁺ evoked by 17β-estradiol may activate eNOS or nNOS. However, the production of NO in J774.1 cells was not affected by the intracellular calcium ionophore A23187 (Fig. 3). This suggests that Ca²⁺ is not involved in the action of 17β-estradiol on macrophages. The NOS may not be eNOS or nNOS, which possess Ca²⁺ dependency, but may be iNOS. In the stimulation by LPS and INF-γ, expression of iNOS mRNA was detected by RT-PCR and it was enhanced by 17β-estradiol (Fig. 4). This increment of iNOS mRNA was suggested to contribute to the increment of NO primed by 17β-estradiol.

It has been established that 17β-estradiol exerts its activity through the following mechanism: 17β-estradiol binds to an ER, two ERs form a dimer, the dimer binds to an estrogen response element (ERE) in DNA and the transcription of genes is activated. On the other hand, iNOS is regulated in the transcriptional step, and consequently, production of
iNOS results in increased synthesis of NO. ERα is expressed in vascular endothelium, and 17β-estradiol binds to ERα to induce production of eNOS mRNA. Because the expression of iNOS mRNA in J774.1 cells was promoted by 17β-estradiol (Fig. 4), it is suspected that 17β-estradiol bound to an ER in J774.1 and that the ER dimer subsequently bound to an ERE in the 5′ side-flanking region of the iNOS gene. An ERE was searched for in the reported sequence of the 5′ side-flanking region of iNOS gene of mouse macrophages. One consensus sequence to half of the ERE was found 1325 base pairs upstream from the transcription initiation point. It was possibly bound by a monomer of ER, although it is unclear at present whether the ER monomer really binds to this site and affects transcription. However, the full consensus sequence to half of the ERE was not found, and ER dimers were suspected to not bind to this region.

A possibility that other mechanisms besides the transcriptional activation of ER as the mechanism of promoting iNOS expression of J774.1 cells with 17β-estradiol was suggested. Sequences besides ERE for binding with other transcriptional factors were searched for in the 5′-side flanking region of the iNOS gene. Possible binding sequences that can be activated by IFN-γ or LPS were found, for example, IFN-γ response element (IRE), γ-activated stimulated position (GAS), nuclear factor kappa B (NF-κB) and activating protein-1 (AP-1). It is reported that ERs can bind to AP-1 in human neuroblasts and human monocytes. ERs in J774.1 could modify the transcriptional function of AP-1 instead of binding to the ERE sequence in DNA. LPS and IFN-γ bind to Toll-like receptor 4 (TLR4) and interferon receptor (IFNR) on the cell membrane, respectively. Intracellular signal transduction pathways are activated, and finally, NF-κB, AP-1 and binding factors to GAS, to induce the expression of the iNOS gene. Our results suggest that ERα contributes little to iNOS mRNA transcription in J774.1 cells (Figs. 5 and 6). The observations above suggest that 17β-estradiol may participate directly at some point in intracellular signal transduction pathways.

Recently, a membrane-type receptor for progesterone was identified. Progesterone binds to the receptor and suppresses guanylate cyclase activity. Estradiol was not shown to bind to this membrane-type progesterone receptor, but another unknown receptor on the membrane might bind to 17β-estradiol and activate intracellular second messengers.

You et al. and Tomaszewska et al. have demonstrated that 17β-estradiol enhanced NO synthesis in mouse peritoneal macrophages and a mouse macrophage cell line, RAW264.7, respectively. Our results were consistent with their observations. It was demonstrated that 17β-estradiol induced iNOS mRNA in sufficient quantity to produce NO in the mouse macrophage cell line J774.1, but ERα hardly seemed to be involved in the priming activity of 17β-estradiol.

REFERENCES


